FILING ANALYSIS · MONDAY, NOVEMBER 9
HERON THERAPEUTICS, INC. /DE/ HRTX — 8-K: Results of Operations and Financial Condition
negative
Heron Therapeutics announced a definitive agreement to sell substantially all of its assets to CorMedix Therapeutics, a move that implies significant corporate restructuring and potential dilution or value transfer for existing shareholders. The company also reported Q3 2026 financial results with total net revenue of $35.3 million, a 7.8% decrease from Q3 2025.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →